Lisata Amends Kuva Acquisition: $4 Cash, Up to $3 CVR Added, Deadlines Extended
LSTA sits 99% above its 52-week low of $1.81 on elevated volume (2.4× avg).
Summary
Lisata Therapeutics has amended its merger agreement with Kuva Labs, reducing the upfront cash consideration to $4.00 per share from the original $5.00. The revised deal now includes a Contingent Value Right (CVR) component of up to $3.00 per share, tied to specific development milestones for certepetide. This amendment follows previous delays in the acquisition and a recent "going concern" warning issued by Lisata. The deal's continuation, even with revised terms, provides a path forward for the company, with the $4.00 cash component exceeding the current stock price and CVRs offering additional potential value. The tender offer commencement obligation is now June 1, 2026, and the Outside Date is July 6, 2026.
At the time of this announcement, LSTA was trading at $3.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $29.6M. The 52-week trading range was $1.81 to $5.07. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.